Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Home
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Next Post
Previous Post
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
October 12, 2021
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
Read More
Bryan Ball
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in
TSC1
and
TSC2
using the Foundation Medicine genomic database
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
Phase 2, Multicenter, Global, Open-Label Basket Trial of
nab
-Sirolimus for Patients With Inactivating Alterations in
TSC1
and
TSC2
(PRECISION 1)
x
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.